v3.26.3
Restatement of Prior Period Financial Statements - Consolidated Statements of Loss and Comprehensive Loss (Details) - CAD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating expenses    
Research and development (Note 20) $ 13,466,234 $ 15,505,346
General and administrative (Note 20) 9,821,724 8,161,070
Total operating expenses 23,287,958 23,666,416
Interest income (333,415) (812,617)
Unrealized loss on warrant derivative (Note 16) 20,850,381 1,060,353
Foreign exchange loss (gain) 409,409 (249,441)
Comprehensive loss $ (44,214,333) $ (23,664,711)
Basic net loss per share $ (0.61) $ (0.35)
Diluted net loss per share $ (0.61) $ (0.35)
Weighted average Common Shares outstanding, Basic (in shares) (Note 17) 72,330,908 67,321,698
Weighted average Common Shares outstanding, Diluted (in shares) (Note 17) 72,330,908 67,321,698
As Previously Stated    
Operating expenses    
Research and development (Note 20) $ 13,907,206 $ 15,811,020
General and administrative (Note 20) 11,172,046 9,365,129
Total operating expenses 25,079,252 25,176,149
Interest income (333,415) (812,617)
Unrealized loss on warrant derivative (Note 16) 18,962,059 135,958
Foreign exchange loss (gain) 409,409 (249,441)
Comprehensive loss $ (44,117,305) $ (24,250,049)
Basic net loss per share $ (0.61) $ (0.36)
Diluted net loss per share $ (0.61) $ (0.36)
Weighted average Common Shares outstanding, Basic (in shares) (Note 17) 72,330,908 67,321,698
Weighted average Common Shares outstanding, Diluted (in shares) (Note 17) 72,330,908 67,321,698
Restatement Adjustments    
Operating expenses    
Research and development (Note 20) $ (440,972) $ (305,674)
General and administrative (Note 20) (1,350,322) (1,204,059)
Total operating expenses (1,791,294) (1,509,733)
Unrealized loss on warrant derivative (Note 16) 1,888,322 924,395
Comprehensive loss $ (97,028) $ 585,338
Basic net loss per share   $ 0.01
Diluted net loss per share   $ 0.01